100 units tirzepatide Close Retatrutide Vials Single Use Stock Photo 2714964395 Tirzepatide (Month 1) 2.5mg |

In the field of research and development of multi-target receptor agonist drugs, there are currently several multi-receptor agonists under research in the world that have entered the clinical stage

5 For example, recent preclinical and clinical observations highlight the role of gut-derived peptides such as GIP, GLP-2, and to a lesser extent, GLP-1 in the maintenance of overall skeletal health ( Figure 2 ), 6,7,8 opening new avenues for the understanding and potential treatment of bone disorders

Combine with a balanced, protein-forward diet to support GH/IGF-1 anabolic effects

17-22% of tirzepatide recipients and 18% of semaglutide recipients experience nausea, the most common side effect